本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二、 取消议案的情况说明 上海阿拉丁生化科技股份有限公司 关于 2023 年年度股东大会取消部分议案的公告 一、 股东大会有关情况 1、 股东大会的类型和届次： 2023 年年度股东大会 | 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2024-021 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | A 股 | 688179 | 阿拉丁 | 2024/4/15 | 1、 取消议案名称 | 序号 | 议案名称 | | --- | --- | | 8 | 审议《关于续聘公司 2024 年度审计机构的议案》； | 2、 取消议案原因 公司于 2024 年 4 月 17 日召开第四届董事会第十九次会议，审议通过了《关 于取消 2023 年年度股东大会部分议案的议案》。公司经过与大华会计师事务所 （特 ...

Group 1: Company Overview and Acquisition - Aladdin Biochemical Technology Co., Ltd. acquired Yuanye Bio to enhance its product line in biochemical reagents, addressing gaps in its offerings and creating synergies with Yuanye's established brand and product range [2] - Yuanye Bio specializes in the R&D, production, and sales of research reagents, with a strong presence in various industrial sectors including pharmaceuticals and food safety [2] Group 2: Financial Performance and Trends - The fourth quarter is traditionally the peak season for revenue, contributing the highest percentage to annual income [2] - The decline in the life sciences segment last year was primarily due to macroeconomic factors and a high sales base from specific products in the previous year [2] - The net profit margin has improved significantly since Q3 of last year due to better expense control, with the growth rate of expenses slowing down [4] - Cash flow has been favorable since Q4 of last year, attributed to the completion of inventory stocking goals and a slowdown in raw material procurement [4] Group 3: Market Demand and Inventory Management - Demand from university clients has rebounded as normal teaching and research activities resume, leading to an increase in their proportion of overall sales [3] - Inventory growth is expected to continue but at a slower rate, as historical data shows a correlation between revenue and inventory changes [4] - Generally, distributors do not hold excessive inventory due to the high storage requirements for research reagents, and low inventory turnover is a common characteristic in the industry [3] Group 4: International Market Focus - The overseas market targets similar types of clients as the domestic market, primarily research institutions and enterprises [5] Group 5: Disclosure Information - The investor meeting did not involve any information that requires mandatory disclosure [5]

西部证券股份有限公司 关于上海阿拉丁生化科技股份有限公司 2023 年度持续督导跟踪报告 保荐人（主承销商） （陕西省西安市新城区东新街 319 号 8 幢 10000 室） 西部证券股份有限公司 关于上海阿拉丁生化科技股份有限公司 2023 年度持续督导跟踪报告 西部证券股份有限公司（以下简称"西部证券"或"保荐人"）作为上海阿 拉丁生化科技股份有限公司（以下简称"阿拉丁"或"公司"）持续督导阶段的 保荐人，根据《证券发行上市保荐业务管理办法》（以下简称"保荐办法"）、《上 海证券交易所科创板股票上市规则》（以下简称"上市规则"）以及《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》等相关规定，负责阿拉 丁的持续督导工作，并出具本持续督导年度跟踪报告。 一、持续督导工作情况 | 序号 | 工作内容 | 持续督导工作情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制度，并针对具 | 已建立健全并有效执行持续 督导工作制度，已根据公司的 | | 1 | | | | | 体的持续督导工作制定相应的工作计划。 | 具体情况制定了相应的工作 | | | | 计 ...

（陕西省西安市新城区东新街 319 号 8 幢 10000 室） 西部证券股份有限公司 关于上海阿拉丁生化科技股份有限公司 首次公开发行股票并在科创板上市之保荐总结报告书 西部证券股份有限公司 关于上海阿拉丁生化科技股份有限公司 首次公开发行股票并在科创板上市之保荐总结报告书 保荐人（主承销商） 西部证券股份有限公司（以下简称"西部证券"、"保荐人"）作为上海阿拉 丁生化科技股份有限公司（以下简称"阿拉丁"、"公司"）首次公开发行股票并 在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》等相关规定的 要求，对阿拉丁首次公开发行股票并在科创板上市进行尽职推荐和持续督导，持 续督导期限至 2023 年 12 月 31 日。目前，持续督导期限已满，西部证券根据《证 券发行上市保荐业务管理办法》的有关规定对阿拉丁出具保荐总结报告书，具体 情况如下： 一、保荐人及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐人及保荐代表人对其真实性、准确性、完整性承担法律 责任。 2、保荐人及保荐代表人自愿接受中国证监会对保荐总结报告书相关事项进 行的任何质询和调查。 ...

公司代码：688179 公司简称：阿拉丁 转债代码：118006 转债简称：阿拉转债 上海阿拉丁生化科技股份有限公司 2023 年年度股东大会 会议资料 中国·上海 2024 年 4 月 上海阿拉丁生化科技股份有限公司 2023 年年度股东大会 上海阿拉丁生化科技股份有限公司 2023 年年度股东大会 目录 | 2023 | 年年度股东大会会议须知 3 | | --- | --- | | 2023 | 年年度股东大会会议议程 5 | | 2023 | 年年度股东大会会议议案 7 | | | 议案一：审议《关于<2023 年度董事会工作报告>的议案》 7 | | | 议案二：审议《关于<2023 年度监事会工作报告>的议案》 13 | | | 议案三：审议《关于<2023 年年度报告及其摘要>的议案》 17 | | | 议案四：审议《关于公司 2023 年年度利润分配及资本公积金转增股本方案 | | | 的议案》 18 | | | 议案五：审议《关于<2023 年财务决算报告>的议案》 19 | | | 议案六：审议《关于<2024 年财务预算报告>的议案》 23 | | | 议案七：审议《关于<2023 年度 ...

Group 1: Investor Meeting Overview - The investor meeting took place on April 9, 2024, with both onsite and online participation from various institutions including CITIC Securities and GF Fund [1] - The meeting was attended by the company's board member, deputy general manager, and board secretary Zhao Xin'an [1] Group 2: Market Demand and Product Strategy - Demand from university clients has been recovering quickly as normal teaching and research activities resume, leading to an increase in their proportion [2] - The acquisition of Source Leaf Biology will enhance Aladdin's biochemical reagent product line, addressing existing gaps and creating a synergistic relationship [2] Group 3: Policy Support and Financial Aspects - The People's Bank of China has introduced a re-lending policy for technological innovation and equipment upgrades, with a quota of CNY 500 billion and an interest rate of 1.75%, aimed at boosting investment in technology-oriented SMEs [3] - Aladdin primarily operates on a prepayment model for most customers, with short payment terms and a small accounts receivable scale, ensuring good cash flow [4] Group 4: Industry Comparison and Sales Strategy - Aladdin's SKU count is significantly lower compared to foreign brands, which have larger product ranges due to their longer establishment periods [5] - The company will continue to focus on an e-commerce model while providing direct sales services to large clients, with a dual approach of direct sales and distribution through dealers [6] Group 5: Industry Growth and R&D Investment - In 2023, China's R&D expenditure reached CNY 332.78 billion, an increase of 8.1% from the previous year, with an R&D intensity of 2.64% of GDP, up by 0.09 percentage points [6] - The increase in R&D funding is expected to drive higher sales of consumables in the reagent industry, indicating a long-term growth potential [7] Group 6: Disclosure Statement - The meeting did not involve any information that requires mandatory disclosure [7]

法律声明 上 市 公 司 基础化工 ——业绩稳定增长，外延并购持续赋能 | --- | --- | |-----------------------------|-------------------------------| | 市场数据： | 2024 年 04 月 08 日 | | 收盘价（元） | 15 | | 一年内最高/ 最低（元） | 41.11/10.1 | | 市净率 | 2.9 | | 息率（分红 / 股价） | - | | 流通 A 股市值（百万元） | 2972 | | 上证指数/深证成指 | 3047.05/9394.61 | | --- | --- | |----------------------------------|-------------------------------| | | | | | | | 基础数据 : | 2023 年 12 月 31 日 | | 每股净资产（元） | 5.23 | | 资产负债率 % | 31.16 | | 总股本 / 流通 A 股（百万） | 198/198 | | 流通 B 股/H 股（百万） | -/- | 04-1005-100 ...

证券代码：688179 证券简称：阿拉丁 转债代码：118006 转债简称：阿拉转债 上海阿拉丁生化科技股份有限公司 接待投资者调研活动记录 一、机构调研情况 调研时间：2024年4月3日 调研形式：线上交流 参与交流来访的机构投资者： 鹏华基金、东方红资管 接待人员： 董事、副总经理、董事会秘书赵新安 ...

证券代码：688179 证券简称：阿拉丁 转债代码：118006 转债简称：阿拉转债 上海阿拉丁生化科技股份有限公司 接待投资者调研活动记录 一、机构调研情况 调研时间：2024年4月1日、2024年4月2日 调研形式：线上交流 参与交流来访的机构投资者： 南方基金、财通资管、华商基金 接待人员： 董事、副总经理、董事会秘书赵新安 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's revenue for 2023 reached 403 million yuan, a year-on-year increase of 6.55%, while the net profit attributable to shareholders was 85.83 million yuan, a year-on-year decrease of 7.48%. The fourth quarter showed a revenue of 120 million yuan, a year-on-year increase of 6.79% and a quarter-on-quarter increase of 23.40% [1][2] - The company is focusing on independent research and development to expand its product line and strengthen channel construction, which is expected to open up future growth opportunities. The acquisition of Shanghai Yuanye Biotechnology for approximately 181 million yuan is anticipated to enrich the product line in biochemical reagents and enhance market influence [2][3] - The company has adjusted its profit forecasts for 2024-2025 due to a slowdown in downstream demand, now expecting net profits of 111 million yuan, 137 million yuan, and 165 million yuan for 2024, 2025, and 2026 respectively [1][3] Financial Summary - In 2023, the company invested approximately 51.25 million yuan in R&D, a year-on-year increase of 31.65%, with R&D personnel reaching 187, accounting for 33.04% of total employees [2] - The gross profit margin for 2023 was 60.2%, an increase of 3.62 percentage points year-on-year, while the net profit margin was 21.3%, an increase of 2.11 percentage points year-on-year [3] - The company's earnings per share (EPS) for 2024, 2025, and 2026 are projected to be 0.56 yuan, 0.69 yuan, and 0.83 yuan respectively, with corresponding P/E ratios of 27.3, 22.2, and 18.4 [1][3]